Subcutaneous anifrolumab is superior to placebo in multiple systemic lupus erythematosus disease activity measures at 52 ...
Feb 3 (Reuters) - AstraZeneca said on Tuesday that the U.S. health regulator had rejected its application for an ...
The FDA has granted Breakthrough Therapy designation for litifilimab for the treatment of cutaneous lupus erythematosus, a chronic autoimmune skin disease.
Feb 3 (Reuters) - AstraZeneca said on Tuesday the U.S. health regulator has rejected its application for a self-injectable ...
Our most recent episode of The Expert Series podcast explores the newly released SLE treatment guidelines and how they might affect patient care.
Congress has taken the final steps in the FY 2026 budget process, passing legislation that increases funding for lupus programs, including $27 million - the most in history - for lupus programs at the ...
Flow Space on MSN
‘I Thought Feeling This Bad Was Normal': The Overlooked Signs Your Lupus Needs More Attention
There are a few to keep in mind.
The FDA has issued a complete response letter to AstraZeneca regarding its application for subcutaneous administration of ...
Kyleigh MacGregor plans her life five years at a time. MacGregor has lupus, an incurable disease in which her immune system attacks her body’s organs and tissue. It’s been a year since MacGregor, 31, ...
Biogen’s litifilimab has received Breakthrough Therapy Designation from the US FDA to treat cutaneous lupus erythematosus ...
Investing.com -- AstraZeneca PLC (ST:AZN) stock fell 1.5% in Tuesday morning trade after the U.S. Food and Drug ...
Eventual tapering and withdrawal of steroids in patients with lupus nephritis is recommended to minimize the drugs' adverse effects, but the ideal timing is uncertain. This study followed 136 lupus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results